These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 18812476)

  • 1. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.
    Matthews JE; Stewart MW; De Boever EH; Dobbins RL; Hodge RJ; Walker SE; Holland MC; Bush MA;
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4810-7. PubMed ID: 18812476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects.
    Bush MA; Matthews JE; De Boever EH; Dobbins RL; Hodge RJ; Walker SE; Holland MC; Gutierrez M; Stewart MW
    Diabetes Obes Metab; 2009 May; 11(5):498-505. PubMed ID: 19187286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus.
    Seino Y; Nakajima H; Miyahara H; Kurita T; Bush MA; Yang F; Stewart MW
    Curr Med Res Opin; 2009 Dec; 25(12):3049-57. PubMed ID: 19863477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide.
    Young MA; Wald JA; Matthews JE; Yang F; Reinhardt RR
    Postgrad Med; 2014 May; 126(3):35-46. PubMed ID: 24918790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide.
    Brønden A; Knop FK; Christensen MB
    Clin Pharmacokinet; 2017 Jul; 56(7):719-731. PubMed ID: 28050889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.
    Home PD; Shamanna P; Stewart M; Yang F; Miller M; Perry C; Carr MC
    Diabetes Obes Metab; 2015 Feb; 17(2):179-87. PubMed ID: 25406730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.
    Hompesch M; Jones-Leone A; Carr MC; Matthews J; Zhi H; Young M; Morrow L; Reinhardt RR
    Diabetes Obes Metab; 2015 Jan; 17(1):82-90. PubMed ID: 25263215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
    Trujillo JM; Nuffer W
    Ann Pharmacother; 2014 Nov; 48(11):1494-501. PubMed ID: 25136065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.
    Barrington P; Chien JY; Showalter HD; Schneck K; Cui S; Tibaldi F; Ellis B; Hardy TA
    Diabetes Obes Metab; 2011 May; 13(5):426-33. PubMed ID: 21251178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program.
    Davidson JA; Jones-Leone A; Wilson TH; Nino A; Forero-Schwanhaeuser S; Reinhardt RR
    Postgrad Med; 2017 Nov; 129(8):849-857. PubMed ID: 29083275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus.
    Shaddinger BC; Soffer J; Vlasakakis G; Shabbout M; Weston C; Nino A
    Diabetes Res Clin Pract; 2019 Jun; 152():125-134. PubMed ID: 31004676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus.
    Davis PN; Ndefo UA; Oliver A; Payton E
    Am J Health Syst Pharm; 2015 Jul; 72(13):1097-103. PubMed ID: 26092960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis.
    Kamrul-Hasan ABM; Dutta D; Nagendra L; Bhattacharya S; Singla R; Kalra S
    Medicine (Baltimore); 2024 Jun; 103(25):e38568. PubMed ID: 38905435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
    Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.
    Ahrén B; Carr MC; Murphy K; Perkins C; Rendell M; Mallory J; Wilson T; Johnson S
    Diabetes Res Clin Pract; 2017 Apr; 126():230-239. PubMed ID: 28284167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.
    Irie S; Matsumura Y; Zdravkovic M; Jacobsen LV; Kageyama S
    Int J Clin Pharmacol Ther; 2008 Jun; 46(6):273-9. PubMed ID: 18541123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.
    Rosenstock J; Nino A; Soffer J; Erskine L; Acusta A; Dole J; Carr MC; Mallory J; Home P
    Diabetes Care; 2020 Oct; 43(10):2509-2518. PubMed ID: 32694215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albiglutide: a review of its use in patients with type 2 diabetes mellitus.
    Blair HA; Keating GM
    Drugs; 2015 Apr; 75(6):651-63. PubMed ID: 25777969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.